PRIME-HCC: Preliminary Assessment of Safety and Bioactivity of the Ipilimumab and Nivolumab Combination Prior to Liver Resection (LR) in Hepatocellular Carcinoma (HCC)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Incidence of treatment-emergent adverse events [Safety and Tolerability]
研究概览
简要总结
The PRIME-HCC trial will assess the effects of combination treatment with nivolumab (OPDIVO) and ipilimumab (YERVOY) pre-operatively in hepatocellular carcinoma patients for whom liver resection is planned. The trial will be conducted at a small number of National Health Service hospitals in the UK. Participants will receive two doses of nivolumab and a single dose of ipilimumab in the weeks before their planned surgery.
详细描述
This is a single-arm, open-label study to be conducted in 32 patients at a small number of UK hospitals. The study is in 2 parts: Part 1 will confirm, in a small number of patients, that the treatment regimen is safe and doesn't result in unacceptable delay to liver resection. Part 2 will expand the number of patients studied, and provide the opportunity to assess survival over about 2 years after liver resection. The decision to proceed to Part 2 will be taken with advice from an independent, expert committee.
Patients with early-stage HCC will first undergo screening procedures during a 28-day time window between giving consent and starting drug treatment. Screening procedures will include:
- Medical interview and physical exam
- ECG
- Tumour biopsy
- Tumour imaging by MRI
- Tumour imaging by CT
- Blood and urine samples
- Stool sample (optional)
Patients meeting the protocol-specified criteria will be enrolled and on Day 1 will have the following:
- Medical interview, and physical exam (if required)
- Blood and urine samples
- Intravenous dose of ipilimumab ('YERVOY') 1 milligram per kilogram body weight
- Intravenous dose of nivolumab ('OPDIVO') 3 milligrams per kilogram body weight
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent for the trial.
- •Aged ≥18 years
- •Confirmed diagnosis of HCC
- •Willing to provide tissue from an excisional biopsy of a tumour lesion
- •Have measurable disease by Computed Tomography (CT)-scan or Magnetic Resonance Imaging (MRI) defined by RECIST 1.1 criteria
- •Ineligible for liver transplantation
- •Medically fit to undergo surgery as determined by the treating medical and surgical oncology team
- •ECOG performance status 0 or 1
- •Adequate organ function
- •Overall Child-Pugh class A
- •Female patient of childbearing potential should have a negative serum pregnancy test within 24 h of her first dose of IMP
- •Women of childbearing potential must be willing to use a highly effective method of contraception for the course of the study through 5 months after the last dose of Investigational Medicinal Product (IMP). Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.
- •Sexually active males must agree to use an adequate method of contraception starting with the first dose of IMP through 7 months after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.
排除标准
- •Extrahepatic metastasis
- •Prior systemic anticancer treatment for HCC, including an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody
- •Prior orthotopic liver transplantation
- •Any major surgery within the 3 weeks prior to enrolment
- •Hepatic encephalopathy
- •Ascites that is refractory to diuretic therapy
- •Is currently receiving anti-cancer therapy (chemotherapy, radiation therapy, immunotherapy or biologic therapy) or has participated or is participating in a study of an IMP or used an investigational device within 4 weeks of the first dose of IMP
- •Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy
- •Known history of active Bacillus Tuberculosis (TB)
- •History of known hypersensitivity to any monoclonal antibody or any of their excipients
- •Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer
- •Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
- •Known history of, or any evidence of active, non-infectious pneumonitis
- •Active infection requiring systemic therapy, with exceptions relating to Hepatitis B and C virus infection
- •History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating Principal Investigator (PI)
- •Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- •Pregnant or breastfeeding
- •Known history of Human Immunodeficiency Virus (HIV; HIV 1/2 antibodies)
- •Received a live vaccine within 30 days of first dose of IMP administration. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
研究组 & 干预措施
Treatment Group
Ipilimumab, solution for infusion, 1 milligram per kilogram body weight, once every 3 weeks, for 3 weeks; Nivolumab, solution for infusion, 3 milligrams per kilogram body weight, once every 3 weeks, for 6 weeks
干预措施: Ipilimumab (Biological)
Treatment Group
Ipilimumab, solution for infusion, 1 milligram per kilogram body weight, once every 3 weeks, for 3 weeks; Nivolumab, solution for infusion, 3 milligrams per kilogram body weight, once every 3 weeks, for 6 weeks
干预措施: Nivolumab (Biological)
结局指标
主要结局
Incidence of treatment-emergent adverse events [Safety and Tolerability]
时间窗: Up to Day 127
Safety and tolerability of the nivolumab and ipilimumab combination based on NCI CTCAE v5.0 criteria from the day of first nivolumab and ipilimumab administration to 126 days later
Delay to surgery
时间窗: Up to Day 89
Number of patients with an unplanned delay to surgery to Day 89 or later
Delay to Surgery
时间窗: Up to Day 89
Number of patients with an unplanned delay to surgery to Day 89 or later
Frequency of Treatment-related Adverse Events [Safety and Tolerability]
时间窗: Up to Day 127
Safety and tolerability of the nivolumab and ipilimumab combination based on NCI CTCAE v5.0 criteria from the day of first nivolumab and ipilimumab administration to 126 days later. Treatment-related adverse events (TRAE) are defined as any unfavorable medical occurrence, symptom, or abnormal laboratory finding in a participant that is deemed to be either definitely, probably, or possibly caused by the trial treatment.
次要结局
- Objective response rate(Up to Day 43)
- Pathologic response rate(Up to Day 88 or up to liver resection, whichever came first)
- Objective Response Rate(Up to Day 43)
- Pathologic Response Rate(Up to Day 88 or up to liver resection, whichever came first)